TREATMENT
INITIAL STABILIZATION/THERAPY
Rarely required in absence of concomitant pathology
ED TREATMENT/PROCEDURES
General:
- Primarily symptomatic
- Wash area with mild soap and water
- Remove or avoid offending agent (including washing clothes)
- Cool, wet compresses; especially effective during acute blistering phase
- Antipruritic agents:
- Topical:
- Calamine lotion, corticosteroids (do not penetrate blisters); avoid benzocaine or hydrocortisone-containing products, which may further sensitize skin
- Systemic: Antihistamines, corticosteroids
- Aluminum acetate (Burrows) solution: Weeping surfaces
Irritant dermatitis:
- Remove offending agent
- Wash well with soap and warm water
- Decrease wet/dry cycles (hand washing)
- Alcohol-based cleansers decrease repetitive trauma
- Bland emollient
- Topical steroids for severe cases (ointment preferred), medium to high potency (hands), BID for several weeks
Allergic dermatitis:
- Topical steroids (ointment preferred) BID for 2–3 wk:
- Face: Low potency
- Arms, legs, and trunk: Medium potency
- Hands and feet: High potency
- Oral steroids for severe cases
Rhus dermatitis:
- Follow general measures plus:
- Wash all clothes and pets that have come in contact with the plant; oil persists and is contagious
- Oatmeal baths can provide soothing relief
- Aseptic aspiration of bullae may relieve discomfort
- Severe reaction (>10% TBSA): Systemic corticosteroids for 2–3 wk with gradual taper:
- Premature termination of corticosteroid therapy may result in rapid rebound of symptoms
Shoe dermatitis:
- Follow general measures plus:
- Wear open-toe, canvas, or vinyl shoes.
- Control perspiration: Change socks, use absorbent powder.
Diaper dermatitis:
- Follow general measures plus:
- Topical zinc oxide, petrolatum ointment, or aquaphor
- Change diapers after each soiling
MEDICATION
Systemic:
- Antihistamine (H
1
-receptor antagonist, 1st and 2nd generation):
- Cetirizine: Adults and children >6 yr, 5–10 mg PO daily (peds: Age 2–6 yr, 2.5 mg PO daily BID)
- Diphenhydramine hydrochloride: 25–50 mg IV/IM/PO q6h PRN (peds: 5 mg/kg/24h div. q6h PRN)
- Fexofenadine: 60 mg PO BID or 180 mg PO daily (peds: Age 6–12 yr, 30 mg PO BID)
- Hydroxyzine hydrochloride: 25–50 mg PO IM up to QID PRN (peds: 2 mg/kg/24h PO div. q6h or 0.5 mg/kg IM q4–6h PRN
- Loratadine: 10 mg PO BID
- For refractory pruritus: Doxepin: 75 mg PO daily may be effective.
- Corticosteroid:
- Prednisone: 40–60 mg PO daily (peds: 1–2 mg/kg/24h, max. 80 mg/24h) div. daily/BID
- For refractory pruritis:
- Doxepin: 75 mg PO daily may be effective.
Topical:
- Aluminum acetate (Burrows) solution: Apply topically for 20 min TID until skin is dry.
- Calamine lotion: q6h PRN
- Topical corticosteroid: Triamcinolone ointment 0.025, 0.1%; cream 0.025, 0.1%; lotion 0.025, 0.1% TID or QID daily
- Caution: Do not apply to face or eyelids
First Line
- Topical steroids
- Oral antihistamines
Second Line
Oral steroids
FOLLOW-UP
DISPOSITION
Admission Criteria
Rarely indicated unless severe systemic reaction or significant secondary infection
Discharge Criteria
- Symptomatic relief
- Adequate follow-up with primary care physician or dermatologic specialist
FOLLOW-UP RECOMMENDATIONS
- Follow up with primary care physician in 2–3 days for recheck
- Return to ED for: Facial swelling, difficulty breathing, mucosal involvement causing decreased PO intake
PEARLS AND PITFALLS
- Remove offending agent
- Beware of progression to systemic anaphylaxis (e.g., latex allergy)
- Watch out for concurrent bacterial infections
- Rhus dermatitis wounds are no longer contagious after washed with soap and water:
- Be sure to wash all clothes and animals that have come in contact with plant as oil remains contagious.
ADDITIONAL READING
- Goldner R, Tuchinda P (2012). Irritant Contact Dermatitis in Adults,
Up To Date
, retrieved Jan 13, 2013 from
http://www.uptodate.com/contents/irritant-contact-dermatitis-in-adults
.
- Hogan DJ, ed. (2011). Allergic Contact Dermatitis,
Medscape
. Retrieved Dec 12, 2012 from
http://emedicine.medscape.com/article/1049216-overview
.
- Hogan DJ, ed. (2011). Irritant Contact Dermatitis,
Medscape
. Retrieved Dec 12, 2012 from
http:emedicine.medscape.com/article/1049353-overview
.
- Marx JA, Hockberger RS, Walls RM, et al., eds.
Rosen’s Emergency Medicine: Concepts and Clinical Practice
. 7th ed. St. Louis, MO: Mosby; 2009.
- Rietschel RL, Fowler JF, eds.
Fisher’s Contact Dermatitis
. 6th ed. Ontario, ON: BC Decker; 2008.
CODES
ICD9
- 692.2 Contact dermatitis and other eczema due to solvents
- 692.9 Contact dermatitis and other eczema, unspecified cause
- 692.81 Dermatitis due to cosmetics
ICD10
- L25.0 Unspecified contact dermatitis due to cosmetics
- L25.2 Unspecified contact dermatitis due to dyes
- L25.9 Unspecified contact dermatitis, unspecified cause
COR PULMONALE
Richard E. Wolfe
BASICS
DESCRIPTION
Right ventricular hypertrophy (RVH) or dilation caused by elevated pulmonary artery pressure. RVH due to a
systemic
defect or congenital heart disease is not classified as cor pulmonale.
- Acute cor pulmonale:
- Right ventricle is dilated and muscle wall stretched thin
- Overload due to acute pulmonary hypertension (HTN)
- Most often caused by massive pulmonary embolism
- Chronic cor pulmonale:
- RVH with eventual dilation and right-sided heart failure
- Caused by an adaptive response to chronic pulmonary HTN
- Predominately occurs as a result of alveolar hypoxia
- The pulmonary circulation is a low-resistance, low-pressure system:
- The pulmonary arteries are thin walled and distensible
- Mean pulmonary arterial pressure is usually 12–15 mm Hg
- Normal left arterial pressure is 6–10 mm Hg
- The resulting pressure difference driving the pulmonary circulation is only 6–9 mm Hg
- 3 factors affect pulmonary arterial pressure:
- Cardiac output
- Pulmonary venous pressure
- Pulmonary vascular resistance
- Pulmonary HTN can arise through a number of mechanisms:
- A marked increase in cardiac output
- Left-to-right shunt secondary to congenital heart disease
- Hypoxia:
- The most common cause of increased pulmonary vascular resistance
- Hypoxic pulmonary vasoconstriction is an adaptive vasomotor response to alveolar hypoxia
- A compensatory rise in pressure is seen in the pulmonary arterial system, so flow is maintained across the pulmonary vascular bed.
- Pulmonary embolus causes a similar change by increasing resistance to pulmonary blood flow
- Dramatic rises in blood viscosity or intrathoracic pressure also impede blood flow
- Pulmonary HTN is classified into 5 groups
- Group 1: Pulmonary arterial HTN
- Group 2: Pulmonary HTN owing to left heart disease
- RV dysfunction in this category is not considered cor pulmonale
- Group 3: Pulmonary HTN owing to lung diseases and/or hypoxia
- Group 4: Chronic thromboembolic pulmonary HTN
- Group 5: Pulmonary HTN with unclear multifactorial mechanisms
EPIDEMIOLOGY
Incidence
- ∼86,000 patients die from COPD each yr:
- Associated RV failure is a significant factor in many of these cases, and accounts for 10–30% of heart failure admissions in US.
- In patients >50 yr with COPD, 50% develop pulmonary HTN and are at risk of developing cor pulmonale.
- The course of cor pulmonale is generally related to the progression of the underlying disease process.
- Once cor pulmonale develops, patients have a 30% chance of surviving 5 yr.
ETIOLOGY